{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:30:09Z","timestamp":1774575009601,"version":"3.50.1"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>IntroductionTo examine whether aripiprazole once-monthly (AOM) was more\n                    beneficial than oral aripiprazole (OARI) in the treatment of adults with\n                    schizophrenia during the maintenance phase.<\/jats:p>\n                  <jats:p>MethodsWe performed a systematic review and network meta-analysis of\n                    double-blind, randomized controlled trials that included two of the following\n                    treatments: AOM, OARI, and placebo.<\/jats:p>\n                  <jats:p>ResultsWe identified four studies involving 1830 adults. Relapse rates at\n                    26 weeks were lower for both AOM (odds ratio [OR] 0.240, 95% confidence\n                    interval [CI] 0.169\u20130.341) and OARI (OR=0.306,\n                    95%CI=0.217\u20130.431) than for placebo, although their\n                    treatment outcomes did not differ significantly (OR=0.786,\n                    95%CI=0.529\u20131.168). Rates of all-cause discontinuation\n                    were also lower with AOM (OR=0.300, 95%\n                    CI=0.227\u20130.396) and OARI (OR=0.441,\n                    95%CI=0.333\u20130.582) than with placebo. The rate of\n                    all-cause discontinuation was lower with AOM than with OARI (OR=0.681,\n                    95% CI=0.529\u20130.877)]. Other outcomes did not differ\n                    significantly between AOM and OARI.<\/jats:p>\n                  <jats:p>DiscussionAlthough both AOM and OARI were efficacious in the treatment of\n                    schizophrenia during the maintenance phase, AOM was better accepted than\n                    OARI.<\/jats:p>","DOI":"10.1055\/a-1860-2793","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T19:05:02Z","timestamp":1657047902000},"page":"291-296","source":"Crossref","is-referenced-by-count":3,"title":["Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia\n                    in the Maintenance Phase: A Systematic Review and Network\n                    Meta-Analysis"],"prefix":"10.1055","volume":"55","author":[{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"S Jauhar","year":"2022","journal-title":"Lancet"},{"key":"ref3","first-page":"80","article-title":"Optimizing treatment choices to improve adherence and outcomes in\n                    schizophrenia","author":"J M Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40263-021-00861-6","article-title":"Controversies surrounding the use of long-acting injectable antipsychotic\n                    medications for the treatment of patients with schizophrenia","volume":"35","author":"J M Kane","year":"2021","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment\n                    of schizophrenia: A systematic review and comparative meta-analysis of\n                    randomised, cohort, and pre-post studies","volume":"8","author":"T Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with\n                    nonaffective psychoses: A network meta-analysis","volume":"178","author":"G Ostuzzi","year":"2021","journal-title":"Am J Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute\n                    treatment of adults with multi-episode schizophrenia: a systematic review and\n                    network meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with\n                    schizophrenia, predictors of metabolic dysregulation, and association with\n                    psychopathology: A systematic review and network meta-analysis","volume":"7","author":"T Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating\n                    network meta-analyses of health care interventions: checklist and\n                    explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Controlled clinical trials"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"S Dias","year":"2010","journal-title":"Stat Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random\n                    inconsistency effects","volume":"33","author":"D Jackson","year":"2014","journal-title":"Stat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic\n                    schizophrenia: A placebo-controlled 26-week study","volume":"64","author":"T A Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"S R Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: Double-blind,\n                    randomised, non-inferiority study","volume":"205","author":"W W Fleischhacker","year":"2014","journal-title":"Br J Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"G Salanti","year":"2014","journal-title":"PLoS ONE"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network\n                    meta-analysis","volume":"17","author":"A Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results\n                    of network meta-analysis","volume":"16","author":"T Papakonstantinou","year":"2020","journal-title":"Campbell Systematic Reviews"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with\n                    schizophrenia: A 52-week, multicenter, randomized, double-blind,\n                    placebo-controlled study","volume":"73","author":"J M Kane","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.schres.2014.12.013","article-title":"Efficacy and safety of aripiprazole once-monthly in Asian patients with\n                    schizophrenia: A multicenter, randomized, double-blind, non-inferiority study\n                    versus oral aripiprazole","volume":"161","author":"J Ishigooka","year":"2015","journal-title":"Schizophr Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"J A Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YCO.0000000000000160","article-title":"Ambiguous findings concerning potential advantages of depot antipsychotics: In\n                    search of clinical relevance","volume":"28","author":"P M Haddad","year":"2015","journal-title":"Curr Opin Psychiatry"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1860-2793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:46:45Z","timestamp":1764107205000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1860-2793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":21,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,11,8]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1860-2793","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}